Melasma (Chlosma) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Melasma, also known as chlosma, is characterized by localized, chronic acquired hypermelanosis of the skin that occur due to melanogenesis dysfunction. It is characterized by the appearances of brown macules distributed symmetrically on the sun-exposed area of the body. It generally occurs due to more use of dermatological care products. The disease affects the quality of life of patient, due to frequent facial involvement. Some of the risk factor associated with the disease are pregnancy, sexual hormones, sun exposure, sue of cosmetics, photosensitizing drugs, steroids and inflammatory process of the skin. Patients generally feels lack of motivation to go out, anhedonia, low-self-esteem, dissatisfaction and feeling of shame. The University of Pittsburgh is in the process of developing TCA peel for the treatment of melisma. Allergan, Inc. is in the process of developing hydroquinone topical cream for the treatment of melisma. Some of the companies and universities having the pipeline of melisma include Allergan, Inc., Assiut University, University of Pittsburgh, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.